[Effect and safety analysis of Allergovit standardized mite allergen immunotherapy in patients with allergic rhinitis].
OBJECTIVE
To evaluate the effect and safety analysis of Allergovit standardized dust mite subcutaneous immunotherapy in patients with allergic rhinitis.


METHODS
From Jan 2006 to Jan 2009,425 patients with persistent were treated with Allergovit standardized dust mite allergen in 3 years, which data were retrospectively analyzed. The scores of the rhinoconjunctivitis quality of life were collected per-treatment and three years treatment. VAS (visual analogue scale) of all nasal symptoms and drug use scores were evaluated before treatment and every 6 weeks. The frequency of local and systemic reactions were recorded in the duration of dose escalation and maintenance.


RESULTS
The Overall QOL were significantly improved after 3 years treatment [pre-treatment: 3.8 (2.9; 4.5); post-treatment: 1.1 (1.0; 2.0), P < 0.01]. VAS of all nasal symptoms and drug used scores decreased dramatically after escalation period [pro-treatment: 23. 7 (20.5; 27.8), 3.9 (3.2; 4.7); post-treatment: 2.1 (1.6; 2.2), 0(0;0), P < 0.01]. Local reaction's rate was 3.15%, the frequency systemic reaction's rate was 0.90%.


CONCLUSIONS
The standardized specific allergen immunotherapy for allergic rhinitis is safe and effective.
Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China. zhaoxmzhao@aliyun.com
Xiaoming
X
Zhao
Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China.
Huiqing
H
Wu
Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China.
Lili
L
Lin
Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China.
Qianzu
Q
Liu
Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China.
Xiaomin
X
Li
Department of Otorhinolaryngology Head and Neck Surgery, Zhuhai People's Hospital, Zhuhai 519000, China.
Bin
B
Luo
D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D039981:Pyroglyphidae / Q000276:immunology; D011788:Quality of Life; D012189:Retrospective Studies; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000628:therapy*; D016896:Treatment Outcome; D014612:Vaccines / Q000009:adverse effects* / Q000627:therapeutic use*; D055815:Young Adult
D014612:Vaccines; C099681:allergovit